Dr. Xu is a Principal Biostatistician at the Princess Margaret Cancer Center, a Scientist at the Ontario Cancer Institute, and an Associate Professor of Biostatistics at Dalla Lana School of Public Health, University of Toronto. As Principal-Investigator or co-Investigator, he has been involved in study design, data administration, statistical modeling development and data analysis on different clinical research and human genetic studies. He has published over 250 peer-reviewed papers in the field of statistics, bioinformatics, medical science and human genetics.
Dr. Xu’s research interests focus on clinical trial design and methodology, biostatistics and bioinformatics methodology, statistical genetics, and cancer clinical and translational research.
FUT2 genotype and secretory status are not associated with fecal microbial composition and inferred function in healthy subjects.
Gut Microbes. 2018 Mar 13;:1-24
Radiomic Biomarkers to Refine Risk Models for Distant Metastasis in HPV-related Oropharyngeal Carcinoma.
Int J Radiat Oncol Biol Phys. 2018 Feb 01;:
Cochrane Database Syst Rev. 2018 Jan 25;1:CD003869
Stereotactic radiosurgery for vestibular schwannoma: International Stereotactic Radiosurgery Society (ISRS) Practice Guideline.
J Radiosurg SBRT. 2017;5(1):5-24
Genet Epidemiol. 2017 Nov 26;:
MARK3-mediated phosphorylation of ARHGEF2 couples microtubules to the actin cytoskeleton to establish cell polarity.
Sci Signal. 2017 Oct 31;10(503):
Methods Mol Biol. 2017;1666:343-373
Mol Carcinog. 2017 Sep 11;:
Otolaryngol Head Neck Surg. 2017 Aug 01;:194599817726756
Radiother Oncol. 2017 Aug;124(2):225-231
Scientist, University Health Network
Principal Biostatistician, Princess Margaret Cancer Center, UHN
Associate Professor, Dalla Lana School of Public Health, University of Toronto